BioLife Solutions (BLFS)
NASDAQ:BLFS
BLFS Stock Chart & Stats
$19.65
-$0.09(-0.33%)
At close: 4:00 PM EST
$19.65
-$0.09(-0.33%)
Day’s Range― - ―
52-Week Range$17.86 - $29.62
Previous CloseN/A
Volume44.73K
Average Volume (3M)363.00K
Market Cap
$949.09M
Enterprise Value$933.95M
Total Cash (Recent Filing)$88.93M
Total Debt (Recent Filing)$17.90M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 07, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,300,000
10 Day Avg. Volume392,925
30 Day Avg. Volume363,004
Financial Highlights & Ratios
PEG Ratio2.20
Price to Book (P/B)3.10
Price to Sales (P/S)12.00
P/FCF Ratio108.55
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue9.71
Enterprise Value/Gross Profit15.04
Enterprise Value/Ebitda-116.45
Forecast
1Y Price Target
$33.20Price Target Upside68.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.14
Revenue Forecast (FY)$112.85M
Bulls Say, Bears Say
Bulls Say
Market PositionDominant market share in biopreservation for cell and gene therapies, particularly in late-stage and commercial programs, supports durable recurring revenue and pricing leverage.
Product Portfolio And Cross‑SellingStrategic divestiture from non-core businesses enabled focus on higher-margin products such as CellSeal cryogenic vials and human platelet lysate, creating cross-selling opportunities that can raise revenue per patient as non-media tools gain adoption.
Research And Innovation CapabilityOpening of the Aby J. Mathew Center for Biopreservation Excellence is set to accelerate development of next-generation cryopreservation and cell processing products while showcasing the full product portfolio to potential customers.
Bears Say
Commercial Execution RiskDifficulty securing additional customers or slower-than-expected uptake of products and services, especially in emerging markets, could constrain revenue growth and pressure valuation.
Financial VolatilityA relatively small revenue base increases sensitivity to revenue timing shifts, making near-term financial results more volatile and harder to predict.
Manufacturing Quality RiskManufacturing bag yield problems are creating headwinds to gross margins and represent a notable operational risk until production yields stabilize.
BioLife Solutions News
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $17.86 and its highest was $29.62 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $949.09M.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Feb 26, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.052.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is 0.02.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 48,300,000 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 7.651%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.20 (68.96% Upside)
$33.20 (68.96% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 60.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.00%
12-Months-Change
Fundamentals
Return on Equity
-3.40%
Trailing 12-Months
Asset Growth
1.07%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BLFS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong top-line growth (29% YoY), significant improvement in adjusted EBITDA and a return to profitability, strengthened liquidity after divesting a product line, and clear 2026 guidance signaling continued growth and expected GAAP profitability. Notable challenges include a decline in gross margin driven by product mix and bag-yield issues (a 2–3 point gross margin headwind in H2 2025), customer/product concentration, a one-time tax true-up that boosted margins, and longer adoption cycles for strategic cross-sell and partnership initiatives. On balance, operational execution, cash position, market leadership in BPM, and improved profitability outweigh the headwinds, though the margin and concentration risks merit monitoring.View all BLFS earnings summariesBLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
BLFS Stock 12 Month Forecast
Average Price Target
$33.20
▲(68.96% Upside)
Technical Analysis
Azenta
―
Staar Surgical
―
Pulse Biosciences
―
Sanara MedTech
―
Kestra Medical Technologies Ltd.
―
Ownership Overview
Currently, No data available
---